Delayed graft function and rejection are risk factors for cytomegalovirus breakthrough infection in kidney transplant recipients

Risk Factors for Failure of Primary (Val)ganciclovir Prophylaxis Against Cytomegalovirus (CMV) Infection and Disease in Solid Organ Transplant (SOT) Recipients

(2019) Mark P Khurana et al.   Open Forum Infectious Diseases

Clinical Outcomes of Valganciclovir Prophylaxis in High Risk (D+/R‐) Renal Transplant Recipients Experiencing Delayed Graft Function

(2019) Sari R Freedman et al.   Transplant Infectious Disease

Valganciclovir Pharmacokinetics in Patients Receiving Oral Prophylaxis Following Kidney Transplantation and Model-Based Predictions of Optimal Dosing Regimens

(2018) Thomas Tängdén et al.   CLINICAL PHARMACOKINETICS

Rituximab as Induction Therapy After Renal Transplantation: A Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Safety

(2015) M. W. F. van den Hoogen et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Electronic Estimations of Renal Function Are Inaccurate in Solid-Organ Transplant Recipients and Can Result in Significant Underdosing of Prophylactic Valganciclovir

(2013) J. Trevillyan et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Extended Valganciclovir Prophylaxis in D+/R− Kidney Transplant Recipients is Associated With Long-Term Reduction in Cytomegalovirus Disease: Two-Year Results of the IMPACT Study

(2010) Atul Humar et al.   TRANSPLANTATION

Pharmacokinetics of Low and Maintenance Dose Valganciclovir in Kidney Transplant Recipients

(2008) C. E. Chamberlain et al.   AMERICAN JOURNAL OF TRANSPLANTATION